Show simple item record

dc.contributor.authorAnones_ES
dc.date.accessioned2015-08-25T14:52:01Z
dc.date.available2015-08-25T14:52:01Z
dc.date.issued2001es_ES
dc.identifier.citationAnon (2001) Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus. Rev Panam Salud Publica;9(5) 345-354,mayo 2001. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500020&lng=pt&nrm=iso&tlng=eses_ES
dc.identifier.urihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500020&lng=pt&nrm=iso&tlng=eses_ES
dc.identifier.urihttps://iris.paho.org/handle/10665.2/7834
dc.relation.ispartofseriesRev Panam Salud Publica;9(5),mayo 2001es_ES
dc.subjectVIH-1es_ES
dc.subjectTransmisión perinatales_ES
dc.subjectAntirretrovíricoses_ES
dc.subjectPrevención y Mitigaciónes_ES
dc.subjectCesáreaes_ES
dc.titleUso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del viruses_ES
dc.title.alternativeRecommendations on the use of antiretroviral agents in pregnant women infected with HIV-1en_US
dc.typeJournal articlesen_US
dc.rights.holderPan American Health Organizationen_US
dc.description.notesIn February 1994, a clinical trial by the Pediatrics AIDS Clinical Trials Group (PACTG 076) demonstrated, for the first time, that it was possible to reduce the risk of vertical transmission of human immunodeficiency virus type 1 (HIV-1) by nearly 70 percent by means of a triple therapeutic regimen: 1) oral zidovudine (ZDV) beginning anytime between the 14th and 34th week of gestation until the end of pregnancy; 2) intravenous ZDV during pregnancy, and 3) administration of oral ZDV to neonates during the first 6 weeks of life. Later, epidemiologic studies performed in the United States of America and France showed that this regimen drastically reduced perinatal transmission in clinical practice. Since then, important strides have been made, not only in terms of treatment (new drugs and highly effective therapeutic regimens) and diagnosis (tests that can measure the viral load), but also in terms of an increased understanding of the pathogenesis of perinatal transmission of HIV-1. This report contains: a) a review of special considerations to be kept in mind when administering antiretroviral agents to pregnant women; b) a current overview of the results of clinical and epidemiologic trials dealing with the prevention of perinatal transmission of HIV-1; c) a look at the use of tests for measuring HIV-1 RNA (viral load) during pregnancy; d) the most recent recommendations on the use of antiretroviral chemoprophylaxis and elective cesarean section for reducing perinatal viral transmission. These recommendations apply to the United States, and other countries may prefer to use different approaches.(AU)en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record